Emerging drug target in pancreatic cancer: placing Sirtuin 1 on the canvas

Marc Giry Laterriere, Andreia V. Pinho, Nils Eling, Lorraine Chantrill, Ilse Rooman

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

Sirtuin 1 is a protein deacetylase that regulates a large number of proteins often functionally implicated in tumor development and progression. Its pleiotropic function has turned SIRT1 into an attractive chemotherapeutic target, underscored by very promising preclinical results with SIRT1 inhibitors in the treatment of chronic myeloid leukemia. Here, we revisit the studies on SIRT1 as an emerging target for therapy in pancreatic cancer, a tumor with dismal outcomes for which currently few therapeutic options are available. We highlight those potential SIRT1 target genes that are commonly affected in pancreatic cancer according to recent genomic analyses.

LanguageEnglish
Pages463-468
Number of pages6
JournalCurrent Cancer Drug Targets
Volume15
Issue number6
DOIs
Publication statusPublished - 1 Jan 2015
Externally publishedYes

Fingerprint

Sirtuin 1
Pancreatic Neoplasms
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pharmaceutical Preparations
Neoplasms
Proteins
Therapeutics
Genes

Keywords

  • Chemotherapy
  • Deleted in breast cancer 1
  • Genomic
  • Mutation
  • Pancreas
  • Personalized medicine
  • Sirtuin 1

Cite this

Laterriere, Marc Giry ; Pinho, Andreia V. ; Eling, Nils ; Chantrill, Lorraine ; Rooman, Ilse. / Emerging drug target in pancreatic cancer : placing Sirtuin 1 on the canvas. In: Current Cancer Drug Targets. 2015 ; Vol. 15, No. 6. pp. 463-468.
@article{eb4d75759b14468eb77db10d76d0dad7,
title = "Emerging drug target in pancreatic cancer: placing Sirtuin 1 on the canvas",
abstract = "Sirtuin 1 is a protein deacetylase that regulates a large number of proteins often functionally implicated in tumor development and progression. Its pleiotropic function has turned SIRT1 into an attractive chemotherapeutic target, underscored by very promising preclinical results with SIRT1 inhibitors in the treatment of chronic myeloid leukemia. Here, we revisit the studies on SIRT1 as an emerging target for therapy in pancreatic cancer, a tumor with dismal outcomes for which currently few therapeutic options are available. We highlight those potential SIRT1 target genes that are commonly affected in pancreatic cancer according to recent genomic analyses.",
keywords = "Chemotherapy, Deleted in breast cancer 1, Genomic, Mutation, Pancreas, Personalized medicine, Sirtuin 1",
author = "Laterriere, {Marc Giry} and Pinho, {Andreia V.} and Nils Eling and Lorraine Chantrill and Ilse Rooman",
year = "2015",
month = "1",
day = "1",
doi = "10.2174/1568009615666150512102957",
language = "English",
volume = "15",
pages = "463--468",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

Emerging drug target in pancreatic cancer : placing Sirtuin 1 on the canvas. / Laterriere, Marc Giry; Pinho, Andreia V.; Eling, Nils; Chantrill, Lorraine; Rooman, Ilse.

In: Current Cancer Drug Targets, Vol. 15, No. 6, 01.01.2015, p. 463-468.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Emerging drug target in pancreatic cancer

T2 - Current Cancer Drug Targets

AU - Laterriere, Marc Giry

AU - Pinho, Andreia V.

AU - Eling, Nils

AU - Chantrill, Lorraine

AU - Rooman, Ilse

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Sirtuin 1 is a protein deacetylase that regulates a large number of proteins often functionally implicated in tumor development and progression. Its pleiotropic function has turned SIRT1 into an attractive chemotherapeutic target, underscored by very promising preclinical results with SIRT1 inhibitors in the treatment of chronic myeloid leukemia. Here, we revisit the studies on SIRT1 as an emerging target for therapy in pancreatic cancer, a tumor with dismal outcomes for which currently few therapeutic options are available. We highlight those potential SIRT1 target genes that are commonly affected in pancreatic cancer according to recent genomic analyses.

AB - Sirtuin 1 is a protein deacetylase that regulates a large number of proteins often functionally implicated in tumor development and progression. Its pleiotropic function has turned SIRT1 into an attractive chemotherapeutic target, underscored by very promising preclinical results with SIRT1 inhibitors in the treatment of chronic myeloid leukemia. Here, we revisit the studies on SIRT1 as an emerging target for therapy in pancreatic cancer, a tumor with dismal outcomes for which currently few therapeutic options are available. We highlight those potential SIRT1 target genes that are commonly affected in pancreatic cancer according to recent genomic analyses.

KW - Chemotherapy

KW - Deleted in breast cancer 1

KW - Genomic

KW - Mutation

KW - Pancreas

KW - Personalized medicine

KW - Sirtuin 1

UR - http://www.scopus.com/inward/record.url?scp=84939783290&partnerID=8YFLogxK

U2 - 10.2174/1568009615666150512102957

DO - 10.2174/1568009615666150512102957

M3 - Review article

VL - 15

SP - 463

EP - 468

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 6

ER -